Your session is about to expire
← Back to Search
Endothelin Receptor Antagonist
Bosentan for Stress-Related High Blood Pressure (End-Stress Trial)
N/A
Waitlist Available
Led By Ryan Harris, Ph.D.
Research Sponsored by Augusta University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Lean adults (BMl <25 kg/m^)
Obese adults (BMl > 30 kg/m^)
Must not have
Using medications that affect vascular tone (i.e., nitrates, etc.)
Postmenopausal women
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and 3 days
Summary
This trial will study how our bodies respond to stress by looking at the role of endothelin-1.
Who is the study for?
This trial is for Black and White adults, ages 18-50, who are either lean (BMI < 25) or obese (BMI > 30). It's not for those on low-salt diets, with severe underweight or extreme obesity issues, cardiovascular diseases, pregnant women, uncontrolled high blood pressure patients, or those taking certain medications.
What is being tested?
The study tests how a drug called Bosentan affects blood pressure response to stress compared to a placebo. The goal is to understand the role of endothelin-1 based on previous animal studies by the investigators.
What are the potential side effects?
While specific side effects aren't listed here, Bosentan can generally cause liver problems, headache, anemia (low red blood cell count), respiratory tract infection and may interact with other medications.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My body mass index (BMI) is less than 25.
Select...
I am considered obese with a BMI over 30.
Select...
I am a man or a premenopausal woman aged between 18 and 50.
Select...
My BMI is under 25.
Select...
I am considered obese with a BMI over 30.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I am taking medication that affects blood vessel function.
Select...
I am a woman who has gone through menopause.
Select...
My high blood pressure is not under control.
Select...
I have a history of rheumatoid arthritis.
Select...
I am not taking medications like glyburide or cyclosporine.
Select...
My BMI is either below 16 or above 40.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline and 3 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and 3 days
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Flow-Mediated Dilation (FMD)
Secondary study objectives
Arterial Stiffness Evaluation (PWV)
Blood Pressure
Femoral blood flow
+2 moreSide effects data
From 2013 Phase 4 trial • 105 Patients • NCT0032329714%
Diarrhoea
14%
Oedema peripheral
14%
Headache
10%
Flushing
10%
Bronchitis
10%
Vertigo
10%
Palpitations
10%
Nasopharyngitis
8%
Respiratory tract infection
6%
Depression
6%
Dyspnoea
6%
Right ventricular failure
6%
Vision blurred
6%
Presyncope
6%
Pulmonary hypertension
4%
Upper respiratory tract infection
4%
Anaemia
4%
Pulmonary arterial hypertension
4%
Bronchopneumonia
2%
Uterine haemorrhage
2%
Nausea
2%
Cough
2%
Acute coronary syndrome
2%
Breast cancer
2%
Hypoxia
2%
Cardiovascular disorder
2%
Haemoglobin decreased
2%
Death
2%
Skin ulcer
2%
Back pain
2%
Chest discomfort
2%
Walking distance test abnormal
2%
Haemoptysis
2%
Coronary artery disease
2%
Cardiac failure
2%
Pancreatic neoplasm
2%
Mitral valve incompetence
2%
Inguinal hernia
2%
Circulatory collapse
2%
General physical health deterioration
2%
Urinary tract infection
2%
Asthenia
2%
Respiratory syncytial virus infection
2%
Gangrene
2%
Sinusitis
2%
Hypertension
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
Sildenafil
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: BosentanExperimental Treatment1 Intervention
Sub-Chronic (3 days) Bosentan 250mg/day.
Group II: PlaceboPlacebo Group1 Intervention
Stress response and endothelial function will be determined following a three day treatment of placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bosentan
2010
Completed Phase 4
~1530
Find a Location
Who is running the clinical trial?
Augusta UniversityLead Sponsor
215 Previous Clinical Trials
85,370 Total Patients Enrolled
National Heart, Lung, and Blood Institute (NHLBI)NIH
3,938 Previous Clinical Trials
47,791,978 Total Patients Enrolled
Ryan Harris, Ph.D.Principal InvestigatorAugusta University
2 Previous Clinical Trials
32 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- My body mass index (BMI) is less than 25.You are pregnant.You are on a diet that limits your salt intake.I am considered obese with a BMI over 30.I have a heart, lung, kidney, liver, brain, or metabolic condition.I am taking medication that affects blood vessel function.I am a woman who has gone through menopause.My high blood pressure is not under control.I have a long-term history of chronic pain.I have a history of rheumatoid arthritis.I am a man or a premenopausal woman aged between 18 and 50.My BMI is under 25.I am considered obese with a BMI over 30.I am not taking medications like glyburide or cyclosporine.My liver may not be working properly.My BMI is either below 16 or above 40.
Research Study Groups:
This trial has the following groups:- Group 1: Placebo
- Group 2: Bosentan
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
High Blood Pressure Patient Testimony for trial: Trial Name: NCT02116335 — N/A